Boehringer Sues Apotex To Protect Zantac Patent

Law360, New York (February 1, 2008, 12:00 AM EST) -- Boehringer Ingelheim Pharmaceuticals Inc. is suing Apotex Inc., claiming the Canadian company’s generic version of its over-the-counter heartburn treatment Zantac infringes a Boehringer patent.

In a complaint filed Thursday in the U.S. District Court for the District of Delaware, the German drugmaker’s U.S. subsidiary alleges that a recent abbreviated new drug application filed by Apotex with the U.S. Food and Drug Administration infringes a patent held by Boehringer that covers flavor-coated tablets.

The patent, U.S. Patent Number 5,098,715, is used in the manufacturing process of Boehringer’s...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.